Aviceda Therapeutics to present on AVD-104 at ASRS 2023 and OIS

Article

The company plans to share the first-in-human safety data from the Phase 2/3 SIGLEC trial evaluating intravitreal AVD-104.

A digital rendering of an eye made out of binary code, 0 and 1. Image credit: ©Ayesha – stock.adobe.com

The company plans to share the first-in-human safety data from the Phase 2/3 SIGLEC trial evaluating intravitreal AVD-104. Image credit: ©Ayesha – stock.adobe.com

Aviceda Therapeutics has shared its upcoming presentations at the American Society of Retina Specialists (ASRS) and the OIS Retina Innovation Summit Meetings. These presentations will focus on the company’s lead ophthalmic clinical asset, AVD-104, a novel glycan-coated nanoparticle for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD)1.

Mohamed Genead, MD, Chief Executive Officer & Co-Founder, Aviceda Therapeutics said in the press release that the company is looking forward to sharing these insights, “We are excited about Aviceda's presence at ASRS this year. AVD-104 was engineered with dual mechanism of action to target both the cellular immune dysfunction and complement implicated in AMD progression. We look to usher in a new paradigm for safer and effective treatment of GA associated with AMD.”1

Aviceda’s presentations are as follows:

July 27, 2023 – OIS Retina Innovation Summit, Seattle, WA

  • Title: AVD-104, A Novel Glyco-Mimetic Nanoparticle for the Treatment of Geographic Atrophy from Macular Degeneration
  • Presenter: Tarek S. Hassan, MD, Chief Development Officer, Aviceda Therapeutics.

July 29, 2023 – American Society of Retina Specialists Annual Meeting, Seattle, WA

  • Title: Modulation of Macrophages and Complement Dysfunction in Nonexudative AMD Using New Sialic Acid–Coated Nanoparticles
  • Presenter: Carl D. Regillo, MD, Professor of Ophthalmology at Thomas Jefferson University, Chief of the Retina Service of Wills Eye Hospital, and Aviceda’s clinical advisory board member.

“I am excited to present the first-in-human safety data from the Phase 2/3 SIGLEC trial evaluating intravitreal AVD-104. This drug may the first next generation treatment for GA with its dual mechanisms of action that attack critical inflammatory pathways by inhibiting activated retinal macrophages and repolarizing them to their resolution states while also inhibiting amplification of the complement cascade,” said Regillo in the news release1.

Reference:

  1. Aviceda Announces Podium Presentations on AVD-104, a Novel Glyco-Mimetic Nanoparticle for the Treatment of Geographic Atrophy from Macular Degeneration, at American Society of Retina Specialists (ASRS) and the OIS Retina Innovation Summit Meetings. Aviceda Therapeutics. July 19, 2023. Accessed July 20, 2023. https://www.businesswire.com/news/home/20230719121344/en/Aviceda-Announces-Podium-Presentations-on-AVD-104-a-Novel-Glyco-Mimetic-Nanoparticle-for-the-Treatment-of-Geographic-Atrophy-from-Macular-Degeneration-at-American-Society-of-Retina-Specialists-ASRS-and-the-OIS-Retina-Innovation-Summit-Meetings

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.